Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

1.6K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.6K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

1.1K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
1.1K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

938
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
938
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

2.3K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
2.3K
Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

6.4K
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
6.4K
Dysrhythmias II: Classification of Tachyarrhythmias01:28

Dysrhythmias II: Classification of Tachyarrhythmias

325
Tachyarrhythmias are a type of dysrhythmia where the heart rate exceeds 100 beats per minute. Here are some common types of tachyarrhythmias:Sinus TachycardiaSinus tachycardia originates from increased impulses from the sinus node, leading to an elevated heart rate. It is often triggered by stress, fever, or exercise.Patients may experience palpitations, a sensation of a racing heart, dizziness, and chest discomfort.Causes and Risk Factors: Common causes include physical exertion, emotional...
325

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Maltese Study in Determining the Presence of Chronic Obstructive Pulmonary Disease in Metabolic Syndrome.

International journal of chronic obstructive pulmonary disease·2026
Same author

Telomere Length in Metabolic Syndrome: Mechanisms, Epidemiology and Clinical Implications: A Narrative Review.

Diabetes, metabolic syndrome and obesity : targets and therapy·2026
Same author

FAIR foundations of a novel indicator vault for non-communicable diseases in the European Union: feasibility study for effective contextualisation of indicators.

Frontiers in digital health·2026
Same author

Factors predicting cure at one year after administration of radioactive iodine to patients with Graves' disease.

Hellenic journal of nuclear medicine·2025
Same author

A taxonomy of indicators for non-communicable diseases: agreement, definition, and contextual description using diabetes as a case study.

Frontiers in public health·2025
Same author

Chronic Obstructive Pulmonary Disease and Metabolic Syndrome: A Maltese Study on Biomarkers and Clinical Implications.

Diabetes, metabolic syndrome and obesity : targets and therapy·2025
Same journal

Central serous chorioretinopathy associated with topical prostaglandin analogues.

BMJ case reports·2026
Same journal

Aberrant macular artery with absent foveal pit and retained inner retinal layers.

BMJ case reports·2026
Same journal

Post-traumatic cervical dystonia treated with botulinum toxin type A injections to the cranial and cervical muscles.

BMJ case reports·2026
Same journal

Light chain-mediated acute tubulointerstitial nephritis as the sole manifestation of monoclonal gammopathy of renal significance in a young adult.

BMJ case reports·2026
Same journal

Late diagnosis of late onset Fabry disease.

BMJ case reports·2026
Same journal

Pelvic desmoid fibromatosis: a diagnostic and therapeutic challenge.

BMJ case reports·2026
See all related articles

Related Experiment Video

Updated: Nov 22, 2025

Zebra II as A Novel System to Record Electrophysiological Signals in Zebrafish
06:15

Zebra II as A Novel System to Record Electrophysiological Signals in Zebrafish

Published on: August 16, 2024

626

Amiodarone-induced type 2 thyrotoxicosis.

Darryl Portelli1, Simon Mifsud2, Alexia Abela3

  • 1Department of Medicine, Mater Dei Hospital, Msida, Malta.

BMJ Case Reports
|January 9, 2021
PubMed
Summary
This summary is machine-generated.

This case study discusses amiodarone-induced thyrotoxicosis (AIT) type 2, a challenging thyroid condition. Prompt diagnosis and appropriate management, particularly distinguishing between AIT types, are crucial for patient prognosis.

Keywords:
cardiovascular systemendocrinologythyroid disease

More Related Videos

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model
04:39

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model

Published on: March 17, 2023

2.2K
Isolation of Human Atrial Myocytes for Simultaneous Measurements of Ca2+ Transients and Membrane Currents
10:53

Isolation of Human Atrial Myocytes for Simultaneous Measurements of Ca2+ Transients and Membrane Currents

Published on: July 3, 2013

20.8K

Related Experiment Videos

Last Updated: Nov 22, 2025

Zebra II as A Novel System to Record Electrophysiological Signals in Zebrafish
06:15

Zebra II as A Novel System to Record Electrophysiological Signals in Zebrafish

Published on: August 16, 2024

626
Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model
04:39

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model

Published on: March 17, 2023

2.2K
Isolation of Human Atrial Myocytes for Simultaneous Measurements of Ca2+ Transients and Membrane Currents
10:53

Isolation of Human Atrial Myocytes for Simultaneous Measurements of Ca2+ Transients and Membrane Currents

Published on: July 3, 2013

20.8K

Area of Science:

  • Endocrinology
  • Cardiology

Background:

  • Amiodarone, a common antiarrhythmic drug, is known to cause thyroid dysfunction.
  • Thyrotoxicosis, characterized by an overactive thyroid, presents diagnostic challenges, especially when drug-induced.

Observation:

  • A 55-year-old male with atrial fibrillation on amiodarone presented with weight loss, palpitations, and dyspnea.
  • Thyroid function tests indicated thyrotoxicosis (elevated free T4, suppressed TSH) with low interleukin-6.
  • Ultrasound revealed a small thyroid gland with heterogeneous echotexture and decreased vascularity.

Findings:

  • Negative TSH-receptor antibody status and the clinical course suggested amiodarone-induced thyrotoxicosis (AIT) type 2.
  • A rapid decrease in thyroid hormone levels after adding prednisolone to carbimazole supported the diagnosis of AIT type 2.
  • Treatment involved discontinuing carbimazole and continuing prednisolone therapy.

Implications:

  • Accurate differentiation between AIT types is critical for effective management.
  • Timely and appropriate treatment of AIT can significantly improve patient outcomes.
  • This case underscores the complexity of managing amiodarone-induced thyroid dysfunction.